SideBy Care reported IBS symptom relief among virtual program completers. Understand the combined care model, outcome measures and study limitations.
On October 11, 2026, SideBy Care announced that 90% of 100 adults with clinically diagnosed IBS who completed its 14-week virtual program reported overall symptom relief. The company's announcement described real-world outcomes presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville.
Combining behavioral and nutrition support was not a new idea introduced by this report. SideBy Care's release points to AGA and Rome Foundation guidelines as supporting multidisciplinary care that includes brain-gut behavioral therapy and nutrition. In plain language, multidisciplinary care brings together professionals with different areas of expertise rather than asking a single service to address every concern.
That is the relevant starting point for interpreting this announcement. The company presents its program as a way to deliver an existing approach through patients' gastroenterology practices. Its report concerns the outcomes of that delivery model rather than a finding that overturns the previous understanding of IBS care.
The medical role also remains central in the company's description. SideBy Care says the program is ordered through a patient's gastroenterologist and works alongside that clinician's medical treatment plan. Behavioral therapy and dietitian input are therefore presented as parts of coordinated care, not as replacements for medical evaluation or treatment.
For readers accustomed to seeing food advice and behavioral support discussed separately, the distinction matters. The question raised by this report is how those services fit together within a medical plan. It is not whether one category of care should displace all the others.
DigestGenius's discussion of stress and digestive patterns provides additional context for readers interested in the broader gut-brain topic.
The announcement adds a set of patient-reported outcomes to a specific virtual care model. Its main contribution is practical: it describes how behavioral sessions and nutrition support were combined over a defined period. It does not announce a new biological mechanism or a new dietary guideline.
SideBy Care describes its 14-week program as combining cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) with nutrition and lifestyle support. The schedule includes nine virtual brain-gut therapy sessions and five Registered Dietitian sessions.
Those details identify the program that produced the reported results. They should be read as a description of this service rather than as a required schedule for IBS care generally. A session count is not the same thing as evidence that every patient needs that exact number of visits.
The company also lists a Mind-Gut Specialist, a Registered Dietitian and a Care Advocate within its care model. It says the gastroenterologist remains responsible for medical treatment. This places the virtual service within a larger clinical relationship rather than presenting it as a stand-alone answer to digestive symptoms.
The combined design is important to the story. The reported experience involved several forms of support delivered together. Describing it simply as a diet program or a behavioral therapy program would leave out part of the intervention.
The company-reported results include several different measures. Each answers a different question:
The relief figure and the severity-score figure should stay separate. Reporting overall relief is not the same outcome as reaching a specified reduction on a symptom scale. The different percentages are not competing versions of a single result.
An average score change also describes the group rather than every individual. Readers should not interpret the average reduction as the amount of improvement each participant experienced. The announcement provides a group summary, not a promise of a particular personal result.
Experience ratings answer another question again. They describe how participants rated the program. A favorable experience rating should not be treated as interchangeable with symptom improvement or with the severity-score threshold.
Keeping these measures distinct makes the announcement more useful. It allows readers to see that the company reported both symptom outcomes and satisfaction without combining them into one broad claim of success.
The nutrition component places food-related support alongside behavioral care and the gastroenterologist's medical plan. The announcement does not introduce a new universal eating rule. Its practical contribution is the coordinated structure of care rather than a menu readers should copy.
That distinction is especially relevant when an IBS headline becomes a reason to change meals. DigestGenius's resource on putting food advice in a wider symptom context offers a related framework for thinking about dietary information without treating every report as a new restriction list.
The first boundary is the source itself. These findings are described in a company press release rather than a full study report. The release says the abstract would be published in a supplement to the October 2026 issue of The American Journal of Gastroenterology. The underlying abstract text is not included in the release.
The population boundary is equally important. The reported 100 adults had completed the program, but the release does not say how many people started and did not finish. That missing enrollment information prevents readers from placing the completers' results within the experience of everyone who entered the program. Outcomes among people who finish a service do not automatically describe outcomes among all who begin it.
The release does not describe randomization, a control group, blinding or another treatment for comparison. It therefore cannot establish that the program caused the improvement or outperformed another approach. The reported p < .0001 does not supply that missing comparison. Nor does the report separate the effects of behavioral sessions from nutrition support or other care received alongside the program.
The participant profile is also incomplete. The release does not detail age distribution or sex. It also omits IBS subtype, prior treatments and baseline coexisting conditions. Without those details, readers cannot judge how closely the cohort resembles another patient population.
The statistical reporting has gaps beyond the comparison issue. Confidence intervals and full statistical methods are not provided. The release also does not give the number of patients assessed at intermediate time points. These omissions limit a fuller assessment of how the reported results were measured and analyzed.
There is no reported follow-up beyond program completion. The announcement therefore does not establish whether improvements persisted afterward. Results at the end of a program and results maintained over time are different questions.
Transparency about study involvement is another unanswered area. The release does not report funding or author disclosures. It also does not specify SideBy Care's role in study design or data analysis. The company's positive interpretation remains its own assessment rather than independent confirmation.
Finally, the guideline and access statements need their own boundary. The release does not supply the guideline documents it cites or supporting data for its claim that specialist access is limited in many community GI practices. Its care-model description also does not establish availability in every practice or coverage under every insurance plan.
Taken together, these constraints define the appropriate conclusion: this is an early real-world account of reported improvement among program completers. It is a reason to examine coordinated care more closely rather than proof of a universal result.
For adults considering care options, the useful next step is a conversation about support rather than copying a program schedule. A GI clinician can be asked whether behavioral-health and nutrition services are available within or alongside existing care. That discussion can also clarify how progress would be assessed and how food-related advice fits the individual's medical plan.
For daily meals, the report offers context rather than a new restriction to adopt. It puts dietitian input inside a broader approach that also includes behavioral support and ongoing medical care. DigestGenius's framework for preparing a discussion about digestive concerns can help organize questions for a qualified clinician.
The realistic editorial takeaway is modest but useful. Coordinated behavioral and nutrition support deserves attention as part of an individualized IBS care discussion. This announcement gives that conversation a concrete example without turning its reported outcomes into a personal forecast.
Patient-reported IBS symptom relief is the outcome at issue here, and understanding how it was measured helps keep a research result separate from a treatment promise. DigestGenius addresses conflicting gut-health advice through free articles and in-depth resources that explain digestive science and distinguish established evidence from emerging findings.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.
Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog
